ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1455

Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus

Miyu Wakatsuki1, Hiroyuki Yamashita1, Yuuya Akiyama1, Setsuko Oyama1, Shintarou Aozaki1, Ryo Kuwata2, Misa Yamaji1, Takuya Harada1, Kyouko Motomura1, Yuusuke Nakamichi1 and Hiroshi Kaneko3, 1National Center for Global Health and Medicine, Tokyo, Japan, 2Department of Rheumatology, National Center for Global Health and Medicine, Tokyo, Japan, 3Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan

Meeting: ACR Convergence 2023

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cytomegalovirus (CMV) infection is classified as an opportunistic infection that occurs in autoimmune diseases. Systemic lupus erythematosus (SLE) is one of the most frequently reported autoimmune diseases that cause CMV reactivation, but no studies have examined the risk factors in patients with SLE. This study aimed to identify the risk factors of CMV reactivation and disease in patients with SLE undergoing remission induction therapy.

Methods: This study reviewed patients with SLE who received remission induction therapy at our institution from May 2010 to October 2022 and enrolled patients whose CMV pp65 antigen levels were measured within 3 months of admission. Patients with CMV reactivation were divided into two groups, namely, CMV disease (presence of symptoms or end-organ disease) and asymptomatic CMV reactivation. We examined the risk factors associated with CMV reactivation and disease.

Results: CMV reactivation was observed in 64 out of 130 patients. Univariate analysis revealed the association between CMV reactivation and old age (46.5 vs. 39.5; P = 0.02), lower serum albumin levels at admission (2.9 vs. 3.3; P< 0.001), higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (17 vs. 10; P = 0.001) at admission, and increased steroid pulse therapy (64.1% vs. 45.5%; P = 0.04) and immunosuppressive drug use (70.3% vs. 50.0%; P = 0.02) (Table 1). Log-rank tests on the above factors revealed significant differences for all except for steroid pulse therapy. Moreover, the Cox proportional hazards regression analysis on the four factors revealed the association of old age (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.09–3.78, P = 0.026), lower albumin (HR: 2.35, 95% CI: 1.09–5.07, P = 0.029), higher SLEDAI (HR: 1.73, 95% CI: 1.00–2.98, P = 0.048), and immunosuppressive drug use (HR: 1.94, 95% CI: 1.12–3.35, P = 0.018) with CMV reactivation. Receiver operating characteristic (ROC) curve analysis using the above four factors revealed that the sensitivity and specificity were 82.8% and 60.6%, respectively (area under the curve = 0.748, 95% CI: 0.664–0.831) for CMV reactivation when all four factors were present. The log-rank test revealed that CMV reactivation developed more frequently when two or more risk factors were present (Figure 1). Among the 64 cases with CMV reactivation, an increased number of CMV pp65 antigen-positive cells was found in the 25 cases with CMV disease than the 39 cases without the disease (6 vs. 2; P = 0.02) (Table 2). ROC curve analysis revealed that the cutoff value for organ damage development was 12 cells out of 2 slides (sensitivity: 36.0% and specificity: 94.9%).

Conclusion: Old age, low albumin levels, high disease activity, and the use of immunosuppressive drugs are possible risk factors of CMV reactivation in patients with SLE. CMV pp65 antigen-positive cells of 12 per 2 slides were determined for the diagnosis of CMV disease.

Supporting image 1

Table 1. Risk factors of CMV reactivation

Supporting image 2

Figure 1. Cumulative probability of CMV reactivation depending on the number of risk factors

Supporting image 3

Table 2. Comparison of patients with and without CMV disease


Disclosures: M. Wakatsuki: None; H. Yamashita: None; Y. Akiyama: None; S. Oyama: None; S. Aozaki: None; R. Kuwata: None; M. Yamaji: None; T. Harada: None; K. Motomura: None; Y. Nakamichi: None; H. Kaneko: None.

To cite this abstract in AMA style:

Wakatsuki M, Yamashita H, Akiyama Y, Oyama S, Aozaki S, Kuwata R, Yamaji M, Harada T, Motomura K, Nakamichi Y, Kaneko H. Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-factors-of-cytomegalovirus-reactivation-and-disease-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-of-cytomegalovirus-reactivation-and-disease-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology